article · 2017
Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients
In the current study, there were no significant differences in the BDFS and DMFS between patients treated with a dose of <76 and ≥76 Gy, including elective p...
4 citationsDOI: https://doi.org/10.2147/ott.s141224Open accessPDF reported by metadataFull text reported by metadata